She won it! The Max Foundation is thrilled to announce that Pat Garcia-Gonzalez has won the Union for International Cancer Control’s CEO Award for 2018!
The Union for International Cancer Control (UICC) is a membership organization that aims to reduce the global cancer burden and promote greater equity in cancer care. Each year the UICC grants awards that aim to identify and celebrate best practices and inspirational figures among their members.
Pat received the CEO Award at this year’s World Cancer Congress in Kuala Lumpur, for her tremendous contributions to equity in cancer care and her visionary leadership as Chief Executive Officer of The Max Foundation. She was cheered on by friends, colleagues, and Max team members from around the globe.
Said Pat: “It is such an honor to receive this award, but it is not only for me. It’s really for the entire Max team and for all our many partners. My thanks go out to them for their daily efforts in making The Max Foundation possible and working tirelessly to create a world where all people can face cancer with dignity and hope.”
Pat had been one of three finalists for the award, alongside Asem Mansour of King Hussein Cancer Center in Jordan, and Wondu Bekele Woldemariam of Mathiwos Wondu-YeEthiopia Cancer Society. Our thanks and congratulations go out to all three finalists.
The Max Foundation would like to thank all our partners – physicians, pharmaceutical manufacturers, distribution and diagnostics companies, donors and supporters, and of course, patient associations – we could not do what we do with you.
Most of all, we’d like to thank the 18 different patient associations from across Asia that sent letters in support of Pat’s nomination. You are the inspiration for all we do and we are so very grateful for your support.
Visit the UICC website to learn more about the awards, the finalists, and our collective work to reduce the global cancer burden.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
Welcoming our New Vice President of Development
The Max Foundation is pleased to announce the hiring of Wilma Comenat as Vice President of Development of The Max Foundation. Wilma has more than 20 years of experience in the nonprofit sector leading development teams and driving major donor fundraising initiatives. Her previous roles include the Associate Executive Director of JDRF Greater Northwest, Regional Director of Lupus Foundation of America, Inc.’s Pacific Northwest region, and Deputy Executive Director of The Leukemia & Lymphoma Society.
The Max Foundation and Friends of Max Strengthen Partnership
Hyderabad, India– The Max Foundation (Max) and Friends of Max (FOM) proudly announce the formalization of their long standing collaboration supporting people living with chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST) in India. The two organizations signed a landmark Memorandum of Understanding (MOU) at the recent Friends of Max 2015 Leadership Summit attended….
New study confirms an excellent survival rate of cancer patients in a medication donation program
A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.
The Max Foundation uses cookies to improve your experience on our site. Please read our Privacy Policy for more information.
